Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q1 2023

Q1 2023 biggest moves
  • CPRXCPRX

    CATALYST PHARMACEUTICALS

    Added 76%

    now 3.8% of portfolio

  • VTRSVTRS

    Viatris

    Added 69%

    now 3.6% of portfolio

  • DCPHDCPH

    DECIPHERA PHARMACEUTICALS IN

    2.2× the shares

    now 1.8% of portfolio

  • PHRPHR

    Phreesia

    Sold out

    was 0.9% of portfolio

67 changes in all

Top Holdings106 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$521.6M11.6%——
7 qtrssince 2021-Q3
Unchanged
0
??
GLAUKOS CORPDelisted
Bond
271.8M$336.2M7.5%——
8 qtrssince 2021-Q2
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.7M$176.6M3.9%$95.92+5.52%
9 qtrssince 2021-Q1
Increased
64
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

10.4M$171.7M3.8%——
3 qtrssince 2022-Q3
Increased
84
??
NATERA INCDelisted
Bond
101M$164.1M3.7%——
8 qtrssince 2021-Q2
Increased
66
VTRS

Viatris Inc.

16.9M$162.9M3.6%$11.69-29.15%
10 qtrssince 2020-Q4
Increased
83
AHCO

AdaptHealth Corp.

10.6M$131.7M2.9%$20.44-39.20%
14 qtrssince 2019-Q4
Increased
68
144.5M$117.3M2.6%——
9 qtrssince 2021-Q1
Unchanged
0
127.8M$116.9M2.6%——
4 qtrssince 2022-Q2
Unchanged
0
AMED
AMEDDelisted

AMEDISYS INC

1.5M$109.1M2.4%——
4 qtrssince 2022-Q2
Increased
65
146M$104.8M2.3%——
2 qtrssince 2022-Q4
Unchanged
0
98.4M$101.2M2.3%——
3 qtrssince 2022-Q3
Unchanged
0
??
ACCOLADE INCDelisted
Bond
122.6M$96.6M2.2%——
4 qtrssince 2022-Q2
Increased
60
51.8M$96M2.1%——
11 qtrssince 2020-Q3
Decreased
0
??
INSMED INCDelisted
Bond
103.2M$94.4M2.1%——
13 qtrssince 2020-Q1
Increased
51
DCPH
DCPHDelisted

DECIPHERA PHARMACEUTICALS IN

5.2M$80.6M1.8%——
14 qtrssince 2019-Q4
Increased
76
LRMR

Larimar Therapeutics, Inc.

16.9M$76.7M1.7%$6.40-29.20%
12 qtrssince 2020-Q2
Unchanged
0
81.6M$75M1.7%——
7 qtrssince 2021-Q3
Unchanged
0
SPRY

ARS Pharmaceuticals, Inc.

11.1M$72.1M1.6%$8.53-23.68%
2 qtrssince 2022-Q4
Unchanged
0
CNC

Centene Corporation

1.1M$68M1.5%$64.16-1.48%
14 qtrssince 2019-Q4
Increased
73
$4.5B
AUM
106
Positions
Q1 2023
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2021-Q4$4,767,581,000-6.95443977376%
2022-Q1$4,472,946,000-6.17996841585%
2022-Q2$4,848,381,0008.39346149048%
2022-Q3$5,023,740,0003.61685684355%
2022-Q4$4,831,008,337-3.83641794758%
2023-Q1$4,485,670,170-7.14836619832%
Activity profile
$ moved · Q1'23
New17%Increased26%Decreased27%Exited31%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.9 years
<1Q11%1-4Q0%1-2Y26%2Y+62%

Deerfield Management Company, L.P. manages $4.5B across 106 positions as of Q1 2023. Top holdings: NUVL (11.6%), GLAUKOS CORP (7.5%), NBIX (3.9%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$4B
NUVL11.63%
GLAUKOS CORP7.50%
NBIX3.94%
CPRX3.83%
NATERA INC3.66%
VTRS3.63%
AHCO2.94%
TABULA RASA 2.61%
IONIS PHARMA2.61%
AMED2.43%
Other2.34%

Portfolio allocation by GICS sector

Sectors3
Healthcare80.53%
Unknown19.40%
Industrials0.07%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used